# | Filing Date | Period End Date | Type | Report Link |
---|---|---|---|---|
No Data found |
# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Candel Therapeutics (NASDAQ:CADL) reported quarterly losses of $(0.74) per share. This is a 124.24 percent decrease over losses...
GeneDx Holdings Corp. (NASDAQ: WGS) has soared 1,101% this year, attributed to its mix shift towards exome/genome testing and r...
GeneDx Holdings Corp. (NASDAQ: WGS) has soared 1,101% this year, attributed to its mix shift towards exome/genome testing and r...
BioRestorative Therapies announced before the market opened on Thursday that it engaged in substantive licensing discussions wi...
Candel Therapeutics, Inc. (Candel or the Company) (NASDAQ:CADL), a clinical stage biopharmaceutical company focused on developi...
ONMD: 66% | OneMedNet shares are trading higher after the company announced that it has entered into a non-exclusive three-year...